Your browser doesn't support javascript.
loading
Treatment Switches, Patterns, and Outcomes in Adult and Pediatric Patients Undergoing Kidney Transplantation Between 2000 and 2019: A Retrospective United States Claims Database Study.
Geissbühler, Yvonne; Johnson, Jonathan C; Gharbi, Hakam; Aubrun, Elodie; Kuessner, Daniel; Smolskis, John M; Barcelos, Giovanna; Prieto, Luis.
Afiliación
  • Geissbühler Y; Novartis Pharma AG, Basel, Switzerland. Electronic address: yvonne.geissbuehler@novartis.com.
  • Johnson JC; Optum, Eden Prairie, Minnesota, United States.
  • Gharbi H; Novartis Pharma AG, Basel, Switzerland.
  • Aubrun E; Novartis Pharma AG, Basel, Switzerland.
  • Kuessner D; Novartis Pharma AG, Basel, Switzerland.
  • Smolskis JM; Optum, Eden Prairie, Minnesota, United States.
  • Barcelos G; Novartis Pharma AG, Basel, Switzerland; Pfizer AG, Zurich, Switzerland.
  • Prieto L; Novartis Pharma AG, Basel, Switzerland.
Transplant Proc ; 56(6): 1290-1299, 2024.
Article en En | MEDLINE | ID: mdl-39068098
ABSTRACT

BACKGROUND:

Immunosuppressive regimens are imperative for improving patient and graft survival following kidney transplantation in patients with kidney failure. However, real-world evidence regarding treatments and outcomes in these patients is scarce. We sought to describe the treatment switches (assessed by line of treatment [LOT]), patterns, and outcomes in patients who underwent kidney transplantation in the United States.

METHODS:

This retrospective cohort study used claims data from the Optum Research Database in the United States. Adult and pediatric patients undergoing a kidney transplantation between January 1, 2000, and June 30, 2019, who had ≥1 year of baseline and follow-up visits and continuous enrollment in the Optum Research Database, were included.

RESULTS:

Data from 7159 patients (6833, adult; 326, pediatric) were included. The mean age for adult and pediatric patients was 51.4 ± 12.8 years and 10.4 ± 5.1 years, respectively. The mean number of LOTs in patients with ≥1 LOT (n = 7004) was 4.1 ± 2.6 LOTs. Tacrolimus, antiproliferative agents, and prednisone were the most frequently prescribed immunosuppressants. No strong correlations were identified between switching from LOT1 to LOT2 and potential predictors of treatment switches. The proportion of patients who did not experience graft loss gradually decreased between month 3 and month 120 (72%-36%), driven by return to dialysis (66%-18%). A slower decrease was observed for graft rejection (98%-84%), retransplantation (98%-93%), and graft removal (98%-92%).

CONCLUSIONS:

We described treatment switches, patterns, and outcomes in patients who underwent kidney transplantation in the United States. Future analytical studies are needed to test hypotheses derived from these observations.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Bases de Datos Factuales / Trasplante de Riñón / Rechazo de Injerto / Supervivencia de Injerto / Inmunosupresores Límite: Adolescent / Adult / Child / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Transplant Proc Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Bases de Datos Factuales / Trasplante de Riñón / Rechazo de Injerto / Supervivencia de Injerto / Inmunosupresores Límite: Adolescent / Adult / Child / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Transplant Proc Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos